AR127561A1 - Compuestos para el tratamiento de trastornos dependientes de cinasas - Google Patents
Compuestos para el tratamiento de trastornos dependientes de cinasasInfo
- Publication number
- AR127561A1 AR127561A1 ARP220103011A ARP220103011A AR127561A1 AR 127561 A1 AR127561 A1 AR 127561A1 AR P220103011 A ARP220103011 A AR P220103011A AR P220103011 A ARP220103011 A AR P220103011A AR 127561 A1 AR127561 A1 AR 127561A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- compounds
- treatment
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 abstract 2
- 239000000356 contaminant Substances 0.000 abstract 2
- 239000008380 degradant Substances 0.000 abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente divulgación hace referencia a inhibidores de tirosina cinasa de fórmula (I) y Compuesto (1) o a sales farmacéuticamente aceptables de estos. Además, la presente divulgación hace referencia a procesos para la preparación de inhibidores de tirosina cinasa, fórmula (I), y Compuesto (1) o una sal farmacéuticamente aceptable de estos. Reivindicación 1: Un compuesto (1), o una sal farmacéuticamente aceptable de este, que comprende 200 ppm o menos de degradantes o de contaminantes. Reivindicación 2: El compuesto de la reivindicación 1, en donde los contaminantes o degradantes comprenden 4-aminofenol, 4-fluoroanilina, un compuesto de fórmula (a), un compuesto de fórmula (b) o mezclas de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275255P | 2021-11-03 | 2021-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127561A1 true AR127561A1 (es) | 2024-02-07 |
Family
ID=84462825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103011A AR127561A1 (es) | 2021-11-03 | 2022-11-02 | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR127561A1 (es) |
| AU (1) | AU2022383160A1 (es) |
| CA (1) | CA3235602A1 (es) |
| TW (1) | TW202334090A (es) |
| WO (1) | WO2023081253A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3088200A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3088200A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| KR20210102381A (ko) * | 2018-12-13 | 2021-08-19 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CR20210616A (es) * | 2019-06-03 | 2022-03-22 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas |
| WO2021222673A1 (en) * | 2020-04-30 | 2021-11-04 | Exelixis, Inc. | Processes for the preparation of a kinase inhibitor |
| IL302485A (en) * | 2020-11-05 | 2023-06-01 | Exelixis Inc | Kinase inhibitor pharmaceutical preparations |
-
2022
- 2022-11-02 TW TW111141900A patent/TW202334090A/zh unknown
- 2022-11-02 AR ARP220103011A patent/AR127561A1/es unknown
- 2022-11-03 AU AU2022383160A patent/AU2022383160A1/en active Pending
- 2022-11-03 WO PCT/US2022/048770 patent/WO2023081253A1/en active Application Filing
- 2022-11-03 CA CA3235602A patent/CA3235602A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023081253A1 (en) | 2023-05-11 |
| AU2022383160A1 (en) | 2024-05-02 |
| CA3235602A1 (en) | 2023-05-11 |
| TW202334090A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112023020483A2 (pt) | Compostos para inibir nlrp3 e usos dos mesmos | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| CO2023008018A2 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| NI201500031A (es) | Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR127561A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| CO2022015205A2 (es) | Procesos para la preparación de un inhibidor de cinasa | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| BR112021022255A2 (pt) | Composto usado como inibidor de quinase e aplicação do mesmo | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| CR20210364A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| MX2023000521A (es) | Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). | |
| CO5590907A2 (es) | Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento de fallo cognitivo | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| CR9539A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer |